Company Overview
BioVie Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing drug therapies for neurological, neurodegenerative disorders, and advanced liver disease within the United States market. The company functions within the Healthcare sector and specifically the Biotechnology industry, an environment characterized by high-risk research and development aimed at bringing novel treatments to patients with complex conditions. As of the latest available data, the company holds a market capitalization of $10.26M and employs a workforce of 13 individuals, while its annual revenue is not available for the trailing twelve months. These valuation and operational figures indicate that BioVie Inc. is a small-cap entity with limited revenue generation, suggesting it is currently in an early stage of commercialization where resources are primarily allocated to advancing its pipeline rather than generating widespread sales.
Financial Health
The financial profile for the trailing twelve months shows revenue figures that are not available, while the net income stands at $-17,478,136 and EBITDA is recorded at $-17,968,812. The significant gap between the unavailable revenue and the substantial negative net income reveals a cost structure where operating expenses heavily outweigh any current income, which is typical for clinical-stage biotechnology firms focused on research and development. Free cash flow for the period is $-8,277,755, indicating that the company is burning cash to fund its operations and clinical trials, which limits immediate financial flexibility but is necessary for product advancement. All three reported margins—gross margin, operating margin, and profit margin—are listed at 0.0%, a metric that reflects the company's current inability to generate profit from its sales or operations before or after tax adjustments. Regarding the balance sheet, the company holds $20.54M in cash against $314,915 in debt, resulting in a debt-to-equity ratio of 1.64, which suggests a leveraged position relative to equity despite the low absolute debt amount. The current ratio is 7.25, a figure that indicates strong short-term liquidity and the ability to cover short-term obligations with current assets without immediate distress. Return on Equity is -80.7% and Return on Assets is -47.2%, metrics that reveal that management is currently generating negative returns on the capital invested, a common characteristic for pre-revenue companies developing high-cost therapies.
Valuation Assessment
The trailing twelve-month P/E ratio is not available due to the lack of earnings, whereas the forward P/E is listed at -0.31, implying that the market prices the stock based on projected negative earnings or a specific accounting treatment for anticipated losses. The price-to-book ratio is 0.53, which indicates that the market values the company at a discount relative to its book value, suggesting a lack of market premium over the tangible assets recorded on the balance sheet. Alternative valuation metrics include a price-to-sales ratio that is not available and an EV/EBITDA of 0.56, figures that suggest the stock is priced very cheaply relative to its enterprise value and earnings power, though the negative earnings context complicates direct comparisons to profitable peers. The 52-week high is $13.20 and the 52-week low is $1.06, meaning the current trading price sits significantly below the recent high, reflecting the volatility and risk associated with clinical-stage development. The stock exhibits a beta of 0.62, which means its price volatility is lower than the broader market, suggesting that the stock tends to move less drastically than the overall market index during periods of fluctuation.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as not available, preventing a direct comparison of whether earnings are growing faster or slower than revenue in the current fiscal period. Because the company does not pay a dividend, the dividend yield is not available and the payout ratio is 0.0%, confirming that the company reinvests all available earnings and capital back into its research and development efforts rather than distributing income to shareholders. This approach prioritizes funding the advancement of BIV201 and other pipeline assets over providing current income to investors. The overall growth and income profile is defined by a complete absence of current profitability or dividend income, relying entirely on the successful progression of its clinical pipeline to eventually generate revenue and returns.